Antiviral article and antiviral resin composition

Abstract

The present invention provides an antiviral article that is capable of suppressing color problems such as discoloration due to light.　More specifically, the present invention provides an antiviral article that is an article provided with a cured product layer, wherein: the cured product layer comprises a cured product of a curable resin composition and antiviral particles; and the antiviral particles comprise at least one kind of antiviral particles A selected from the group consisting of 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, 2) a mixture of particles containing a styrene polymer derivative compound with particles containing an unsaturated carboxylic acid derivative compound, and 3) particles containing a styrene resin.

Description

[Technical Field]

[0001] The present invention relates to an antiviral article and an antiviral resin composition. [Background technology]

[0002] From the viewpoint of hygiene, antibacterial treatment has conventionally been carried out by applying an antibacterial composition to the surfaces of objects that people touch, such as interior materials for buildings, interior materials for vehicles, office automation equipment, and touch panels.

[0003] For example, the techniques disclosed in Patent Documents 1 to 3 have been proposed for antibacterial compositions or antibacterial articles. However, for viruses such as influenza viruses, merely having antibacterial properties is not sufficient. In other words, the antibacterial compositions or articles disclosed in Patent Documents 1 to 3 sometimes fail to provide satisfactory antiviral properties.

[0004] On the other hand, techniques described in Patent Documents 4 and 5 have been proposed regarding compositions or articles having antiviral properties. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Publication No. 63-265958 [Patent Document 2] Patent No. 3551201 [Patent Document 3] Patent No. 4840048 [Patent Document 4] Patent No. 6145758 [Patent Document 5] Patent No. 6229429 Summary of the Invention [Problem to be solved by the invention]

[0006] The antiviral resin composition of Patent Document 4 contains cuprous oxide particles, etc. Therefore, it is not possible to prevent the color (reddish brown) derived from the color of cuprous oxide.

[0007] The antiviral decorative sheet for interior use of Patent Document 5 is obtained by blending a silver-based inorganic additive or a zinc-based inorganic additive into the coating resin on the outermost surface of the decorative sheet.

[0008] Among the additives disclosed in Patent Document 5, the former silver-based inorganic additive had a problem of discoloring to brown due to light (visible light, ultraviolet light). In particular, when the amount of silver-based inorganic additive added was increased to exhibit antiviral properties, the problem of discoloration due to light became more pronounced.

[0009] An object of the present invention is to provide an antiviral article and an antiviral resin composition that can suppress color problems such as discoloration due to light. [Means for solving the problem]

[0010] In order to solve the above problems, the present invention provides the following [1] to

[13] . [1] An article having a cured layer, an antiviral article, wherein the cured product layer comprises a cured product of a curable resin composition and antiviral particles, and the antiviral particles contain at least one type of antiviral particle A selected from the group consisting of: 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, 2) mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound, and 3) particles containing a styrene resin. [2] The antiviral article according to item 1, comprising 0.5 to 20.0 parts by mass of the antiviral particles A per 100 parts by mass of the cured product. [3] The antiviral article according to item 1 or 2, comprising the cured product layer on a substrate. [4] The antiviral article according to any one of items 1 to 3, wherein the antiviral particles A of 1) and / or 2) have at least one structure selected from the group consisting of styrene, sodium sulfonate, acrylic acid, maleic acid, and fumaric acid. [5] The antiviral article according to any one of items 1 to 4, wherein the cured product layer further contains a phenyl ether derivative compound. [6] The antiviral article according to any one of items 1 to 5, wherein the cured product layer further contains at least one agent selected from the group consisting of an antibacterial agent and an antiallergenic agent. [7] The antiviral article according to any one of items 1 to 6, wherein the antiviral particles further contain antiviral particles B different from the antiviral particles A. [8] The antiviral article according to any one of items 1 to 7, wherein the antiviral particles have two different particle size peaks. [9] An antiviral resin composition comprising a curable resin composition and antiviral particles, wherein the antiviral particles contain at least one type of antiviral particle A selected from the group consisting of: 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, 2) mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound, and 3) particles containing a styrene resin.

[10] The antiviral resin composition according to item 9, further comprising a phenyl ether derivative compound.

[11] The antiviral resin composition according to item 9 or 10, further comprising at least one selected from the group consisting of an antibacterial agent and an antiallergenic agent.

[12] The antiviral resin composition according to any one of items 9 to 11, wherein the antiviral particles further contain antiviral particles B different from the antiviral particles A.

[13] The antiviral resin composition according to any one of items 9 to 12, wherein the antiviral particles have two different particle size peaks. [Effects of the Invention]

[0011] According to the present invention, it is possible to provide an antiviral article and an antiviral resin composition that can suppress color problems such as discoloration due to light. [Brief explanation of the drawings]

[0012] [Figure 1] FIG. 1 is a cross-sectional view showing one embodiment of the antiviral article of the present invention. [Figure 2] FIG. 1 is a cross-sectional view showing another embodiment of the antiviral article of the present invention. [Figure 3] FIG. 1 is a cross-sectional view showing another embodiment of the antiviral article of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0013] [Antiviral products] The antiviral article of the present invention is an article having a cured material layer, wherein the cured material layer comprises a cured material of a curable resin composition and antiviral particles, and the antiviral particles comprise at least one type of antiviral particle A selected from the group consisting of 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, 2) mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound, and 3) particles containing a styrene resin.

[0014] That is, the antiviral particles of the present invention contain antiviral particles A, and the antiviral particles A may be 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound together, 2) mixed particles containing particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound separately, or 3) particles containing a styrene resin, which are different from the above, or any combination of 1) to 3). As will be described in detail later, in the present invention, in addition to the antiviral particles A, antiviral particles B different from the antiviral particles A may also be used in combination, as long as the effects of the present invention are not affected. Hereinafter, the term "antiviral particles" is used to encompass both the antiviral particles A and the antiviral particles B.

[0015] 1(A) to 1(E), 2(A) to 2(D), and 3 are cross-sectional views showing representative embodiments of an antiviral article 100 of the present invention.

[0016] The antiviral article 100 in FIGS. 1(A) to 1(E), 2(A) to 2(D), and 3 has a cured material layer 10 containing a cured material 11 of a curable resin composition and antiviral particles 12.

[0017] The antiviral article 100 in FIGS. 1(A) to 1(E) is formed of a single layer of a cured material layer 10.

[0018] The cured material layer 10 in FIG. 1(A) contains antiviral particles 12 throughout the cured material layer 10 in both the thickness direction (the Z-axis direction in the figure) and the in-plane directions (the directions in the XY plane in the figure). The cured material layer 10 in FIG. 1(B) contains antiviral particles 12 on the surface side (upper side in the figure) of the cured material layer 10. The cured material layer 10 in FIG. 1(C) contains antiviral particles 12 on the surface side (upper side in the figure) and the back side (lower side in the figure) of the cured material layer 10. The cured material layer 10 in FIG. 1(D) contains antiviral particles 12 in a partial region in the in-plane direction on the surface side (upper side in the figure) of the cured material layer 10. The cured material layer 10 in FIG. 1(E) contains antiviral particles 12 in a partial region on the surface side (upper side in the figure) of the cured material layer 10 and in a partial region on the back side (lower side in the figure) of the cured material layer 10.

[0019] 1(A) to 1(E), there are no particular limitations on the locations of the antiviral particles 12 in the cured material layer 10. However, from the viewpoint of enhancing antiviral properties, it is preferable that the antiviral particles 12 are present on the surface that comes into contact with people.

[0020] An antiviral article 100 consisting of a single layer of the cured material layer 10 as shown in Figs. 1(A) to (E) can be obtained, for example, by forming a laminate in which the cured material layer 10 is formed on a substrate having releasability, and then peeling off the substrate having releasability from the laminate.

[0021] The antiviral article 100 in FIGS. 2(A) to 2(D) has a cured material layer 10 on a substrate 20.

[0022] The antiviral article 100 in Fig. 2(A) has a cured material layer 10 covering the entire surface of one side of the substrate 20. The antiviral article 100 in Fig. 2(B) has a cured material layer 10 covering the entire surface of both sides of the substrate 20. The antiviral article 100 in Fig. 2(C) has a cured material layer 10 in a partial region of one side of the substrate 20 (the + side in the Z axis direction in the figure, the direction indicated by the arrow in the figure is the + side). The antiviral article 100 in Fig. 2(D) has a cured material layer 10 in a partial region of one side of the substrate 20 (the + side in the Z axis direction in the figure) and in a partial region of the other side of the substrate 20 (the - side in the Z axis direction in the figure).

[0023] 2(A) to 2(D), the cured material layer 10 may be formed on the entire surface of the substrate 20, or may be formed on a part of the surface of the substrate 20. Furthermore, as shown in FIGS. 2(A) to 2(D), the cured material layer 10 may be formed on only one surface of the substrate 20, or may be formed on both surfaces of the substrate 20.

[0024] The antiviral article 100 in Fig. 3 has a cured material layer 10 on a three-dimensional substrate 20. The three-dimensional substrate 20 in Fig. 3 is a door handle, and Fig. 3 shows a cross-sectional view of the door handle.

[0025] <Cured Product of Curable Resin Composition> The cured material layer contains a cured material of the curable resin composition. In this specification, the "cured material of the curable resin composition" may be abbreviated as "cured material." Note that the curable resin composition essentially means a curable resin, but includes additives for curing the curable resin (such as a curing agent, a curing catalyst, a photopolymerization initiator, and a photopolymerization accelerator).

[0026] The cured product of the curable resin composition mainly serves as a binder resin. By including this cured product, the antiviral article has good scratch resistance and can more easily maintain its antiviral properties over a long period of time.

[0027] Examples of the cured product of the curable resin composition include a cured product of a thermosetting resin composition and / or a cured product of an ionizing radiation-curable resin composition, and among these, a cured product of an ionizing radiation-curable resin composition is preferred from the viewpoints of scratch resistance and production efficiency.

[0028] The thermosetting resin composition is a composition that contains at least a thermosetting resin and is a resin composition that is cured by heating.

[0029] Examples of thermosetting resins include acrylic resins, urethane resins, phenolic resins, urea melamine resins, epoxy resins, unsaturated polyester resins, silicone resins, etc. In addition to these thermosetting resins, a curing agent, a curing catalyst, etc. are added to the thermosetting resin composition as needed.

[0030] Representative examples of ionizing radiation-curable resin compositions include electron beam-curable resin compositions and ultraviolet light-curable resin compositions, and among these, electron beam-curable resin compositions are preferred from the viewpoints of being odorless, less prone to coloration, etc., since no polymerization initiator is required. Furthermore, when the cured product layer contains an ultraviolet light absorber described below, electron beam-curable resin compositions are preferred in that they tend to increase the crosslink density of the cured product layer and tend to improve scratch resistance and contamination resistance.

[0031] The ionizing radiation curable resin composition is a composition containing a compound having an ionizing radiation curable functional group (hereinafter also referred to as "ionizing radiation curable compound").

[0032] The ionizing radiation-curable functional group is a group that crosslinks and cures upon irradiation with ionizing radiation, and preferred examples thereof include functional groups having an ethylenic double bond such as a (meth)acryloyl group, a vinyl group, and an allyl group. Further examples of the ionizing radiation-curable functional group include an epoxy group and an oxetanyl group.

[0033] In this specification, the term "(meth)acryloyl group" refers to an acryloyl group or a methcroyl group, and the term "(meth)acrylate" refers to an acrylate or a methacrylate.

[0034] Furthermore, ionizing radiation refers to electromagnetic waves or charged particle beams that have an energy quantum capable of polymerizing or crosslinking molecules. Typically, ultraviolet (UV) rays and / or electron beams (EB) are used, but it also includes other electromagnetic waves such as X-rays and gamma rays, and charged particle beams such as alpha rays and ion beams.

[0035] Specifically, the ionizing radiation curable compound can be appropriately selected from polymerizable monomers and polymerizable oligomers (sometimes referred to as "polymerizable prepolymers") that have conventionally been used as ionizing radiation curable resins.

[0036] The ionizing radiation curable compound is preferably a compound having two or more ethylenically unsaturated bond groups, and more preferably a polyfunctional (meth)acrylate compound having two or more ethylenically unsaturated bond groups. The polyfunctional (meth)acrylate compound may be either a monomer or an oligomer.

[0037] Among the polyfunctional (meth)acrylate compounds, examples of bifunctional (meth)acrylate monomers include ethylene glycol di(meth)acrylate, bisphenol A tetraethoxydiacrylate, bisphenol A tetrapropoxydiacrylate, and 1,6-hexanediol diacrylate.

[0038] Examples of trifunctional or higher (meth)acrylate monomers include trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, pentaerythritol tetra(meth)acrylate, dipentaerythritol hexa(meth)acrylate, dipentaerythritol tetra(meth)acrylate, and isocyanuric acid-modified tri(meth)acrylate.

[0039] Examples of the polyfunctional (meth)acrylate oligomer include acrylate polymers such as urethane (meth)acrylate, epoxy (meth)acrylate, polyester (meth)acrylate, and polyether (meth)acrylate.

[0040] Urethane (meth)acrylates can be obtained, for example, by reacting a polyhydric alcohol and an organic diisocyanate with a hydroxy (meth)acrylate.

[0041] Preferred epoxy (meth)acrylates are (meth)acrylates obtained by reacting a tri- or higher functional aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, or the like with (meth)acrylic acid; (meth)acrylates obtained by reacting a di- or higher functional aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, or the like with a polybasic acid and (meth)acrylic acid; and (meth)acrylates obtained by reacting a di- or higher functional aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, or the like with a phenol and (meth)acrylic acid.

[0042] The above ionizing radiation curable resins can be used alone or in combination of two or more.

[0043] When the ionizing radiation curable compound is an ultraviolet ray curable compound, the ionizing radiation curable resin composition preferably contains additives such as a photopolymerization initiator and a photopolymerization accelerator.

[0044] The photopolymerization initiator may be one or more selected from acetophenone, benzophenone, α-hydroxyalkylphenone, Michler's ketone, benzoin, benzil dimethyl ketal, benzoyl benzoate, α-acyloxime ester, thioxanthones, and the like.

[0045] The photopolymerization accelerator can reduce polymerization inhibition caused by air during curing and increase the curing rate, and examples thereof include one or more selected from p-dimethylaminobenzoic acid isoamyl ester, p-dimethylaminobenzoic acid ethyl ester, etc.

[0046] The content of the cured product of the curable resin composition is preferably 50% by mass or more, more preferably 70% by mass or more, even more preferably 90% by mass or more, and most preferably 100% by mass, based on the total amount of binder resin. Note that, in this specification, the binder resin is a general term for resin components including not only the curable resin contained in the curable resin composition but also a non-curable resin that can function as a binder in the cured product layer.

[0047] <Antiviral particles> The cured product layer includes a cured product of the curable resin composition and antiviral particles, and the antiviral particles contain at least one type of antiviral particle A selected from the group consisting of 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, 2) mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound, and 3) particles containing a styrene resin. Here, the 3) particles containing a styrene resin are particles that do not contain the unsaturated carboxylic acid derivative compound. As described above, the antiviral particles A in the present invention may be 1) particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound together, 2) mixed particles containing particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound separately, or 3) particles containing a styrene resin, which are different from the above, or any combination of these 1) to 3).

[0048] The antiviral particles A of 1) and / or 2) contain a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, and the components thereof preferably have at least one structure selected from the group consisting of hydrogen, a hydroxyl group, a carboxyl group, a sulfonic acid group, a salt of a carboxyl group, a salt of a sulfonic acid group, a derivative of a carboxyl group, and a derivative of a sulfonic acid group. Specifically, the components preferably have at least one structure selected from the group consisting of styrene, sodium sulfonate, acrylic acid, maleic acid, and fumaric acid, and more preferably have both at least one structure of styrene and sodium sulfonate and at least one structure selected from the group consisting of acrylic acid, maleic acid, and fumaric acid.

[0049] In the present invention, the content ratio of the styrene polymer derivative compound and the unsaturated carboxylic acid derivative compound in the entire antiviral particle A of 1) and / or 2) above is not limited, but if antiviral performance is required only against enveloped viruses, it is sufficient to contain only the styrene polymer derivative compound. In this regard, if antiviral performance is required only against enveloped viruses, the antiviral particle A of the present invention may be in an embodiment using particles containing at least 3) a styrene resin.

[0050] However, in order to ensure that the antiviral particles A of 1) and / or 2) above have antiviral activity against non-enveloped viruses, the activity of which is difficult to inhibit, it is preferable that they contain an unsaturated carboxylic acid derivative compound in addition to a styrene polymer derivative compound, and in the present invention, the mass ratio of styrene polymer derivative compound:unsaturated carboxylic acid derivative compound can be set to, for example, 30:70 to 70:30, or even 40:60 to 60:40. In other words, in order for the antiviral particles A of the present invention to have antiviral activity against both enveloped and non-enveloped viruses, it is preferable to use antiviral particles A of 1) and / or 2) above that contain both a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound.

[0051] Specifically, when the antiviral particles A of 1) and / or 2) above are mixed particles separately containing particles containing a styrene polymer derivative compound (particles Aa) and particles containing an unsaturated carboxylic acid derivative compound (particles Ab), the mass ratio of particles Aa:particles Ab can be set to 30:70 to 70:30, or even 40:60 to 60:40. As these particles Aa and particles Ab, particles containing the respective components and commercially available for various applications may be used as they are, or commercially available solvent-based particles may be dried and molded into particles for use.

[0052] In the present invention, in addition to antiviral particles A, antiviral particles B different from antiviral particles A may be further contained within a range that does not affect the effects of the present invention. Antiviral particles B are not particularly limited as long as they are antiviral particles that do not fall under the category of antiviral particles A specified in 1), 2), and 3) above. When antiviral particles A and antiviral particles B are used in combination, the mass ratio of antiviral particles A:antiviral particles B is not limited, but is preferably set within the range of 10:1 to 50:40.

[0053] The reason why the antiviral particles A of 1) and / or 2) exhibit antiviral properties is not limited to the mechanism speculated below, but for example, influenza viruses invade host cells by binding to sugar chain receptors (the sugar chain ends in neuraminic acid) on the surface of the host cells. However, since the copolymer containing styrene sulfonate has an ionic group similar to neuraminic acid, it is thought that it binds to the virus instead of the host cells, captures the virus, and prevents the virus from binding to the host cell receptor, thereby exerting its antiviral effect. In addition, unsaturated carboxylic acid derivative compounds convert hydroxyl groups (OH) into hydroxyl groups (OH) when they come into contact with water. -) and the hydroxyl groups exert an antiviral effect. The reason why the antiviral particles A in 3) above exhibit antiviral activity against enveloped viruses is not limited to a specific mechanism, but is thought to be due to, for example, an action similar to that of the copolymer containing styrene sulfonate described above.

[0054] Furthermore, in the present invention, the antiviral particles are present in the cured material layer in the form of particles. In other words, the antiviral particles are present in the form of particles without dissolving in the ink for the cured material layer (antiviral resin composition). Therefore, in the process of forming the cured material layer, the antiviral particles tend to float up, making it possible to easily cause the antiviral particles to be unevenly distributed on one surface side of the cured material layer. Furthermore, by causing the antiviral particles to be unevenly distributed on one surface side of the cured material layer, it is possible to reduce the amount of antiviral particles added necessary to achieve a predetermined antiviral property, and therefore it is possible to easily prevent a decrease in the scratch resistance of the cured material layer.

[0055] To facilitate uneven distribution of antiviral particles on the surface of the cured material layer, it is preferable to select a curable resin composition that satisfies the relationship "specific gravity of antiviral particles < specific gravity of curable resin composition." Furthermore, using antiviral particles with a high degree of polarity is preferable because it facilitates uneven distribution of the antiviral particles on the surface of the cured material layer. Furthermore, when the solvent contained in the ink for the cured material layer volatilizes, it is possible to facilitate floating of the antiviral particles to the surface of the cured material layer, thereby facilitating uneven distribution of the antiviral particles near the surface of the cured material layer.

[0056] The shape of the antiviral particles is not particularly limited, and examples thereof include spheres, ellipsoids, polyhedrons, and scales.

[0057] The average particle size of the antiviral particles is preferably 0.1 to 10.0 μm, more preferably 0.5 to 8.0 μm, and even more preferably 1.0 to 7.0 μm.

[0058] By setting the average particle size to 0.1 μm or more, the ink for the cured layer can be more stable, while by setting the average particle size to 10.0 μm or less, it is possible to easily prevent the antiviral particles from protruding from the surface of the cured layer, resulting in poor appearance, reduced scratch resistance and stain resistance, and whitening of the coating film.

[0059] The average particle size of the antiviral particles is preferably within the above-mentioned range, but even if the antiviral particles in the ink for the cured material layer aggregate before the cured material layer is completely cured and the particle size appears larger, there is no problem in expressing antiviral performance.

[0060] When the average particle size of the antiviral particles is defined as D and the thickness of the cured material layer is defined as T, D / T is preferably 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less.

[0061] By setting D / T to 1.0 or less, it is possible to easily prevent poor appearance, reduced scratch resistance and stain resistance, and whitening of the coating film caused by the antiviral particles protruding from the surface of the cured product layer.

[0062] The lower limit of D / T is not particularly limited, but is usually 0.01 or more, and preferably 0.05 or more.

[0063] In this specification, the average particle size refers to the mass average value d50 measured in particle size distribution measurement by laser light diffraction method.

[0064] In the present invention, antiviral particles may have two different particle size peaks. The two different particle size peaks are derived from, for example, the combined use of two or more types of antiviral particles having different components (and therefore different particle sizes). Specifically, the two different particle size peaks may be derived from a combination of the particles 1) to 3) above in antiviral particles A, or may be derived from the inclusion of antiviral particles B in addition to antiviral particles A.

[0065] The content of the antiviral particles A is preferably 0.5 to 20.0 parts by mass, more preferably 1.0 to 13.0 parts by mass, and even more preferably 3.0 to 10.0 parts by mass, per 100 parts by mass of the cured product.

[0066] By setting the content of the antiviral particles A to 0.5 parts by mass or more, it is possible to easily improve the antiviral properties.

[0067] By setting the content of antiviral particles A to 20.0 parts by mass or less, it is possible to prevent deterioration in coating film properties such as coating film strength and scratch resistance. Furthermore, by setting the content of antiviral particles to 20.0 parts by mass or less, it is possible to easily prevent deterioration in stain resistance and whitening of the coating film due to the antiviral particles protruding from the surface of the cured product layer.

[0068] <Additives> The cured layer is Phenyl The composition may contain additives such as ether derivative compounds, antioxidants, light stabilizers, ultraviolet absorbers, extender pigments, antibacterial agents, antiallergens, antifungal agents, flame retardants, lubricants, foaming agents, and deodorizers.

[0069] 《 Phenyl Ether derivative compounds Phenyl The ether derivative compound can be contained in the cured product layer to complement the antiviral performance.

[0070] Phenyl An example of the ether derivative compound is polyoxyethylene alkyl ether, which is known to be an ether-type nonionic surfactant capable of exhibiting antiviral properties.

[0071] Phenyl The content of the ether derivative compound is preferably 0.1 to 5.0 parts by mass per 100 parts by mass of the cured product. By including 0.1 part by mass or more, the antiviral performance of the cured product layer can be complemented, and by including 5.0 parts by mass or less, the surface performance of the cured product layer, such as scratch resistance and stain resistance, can be maintained.

[0072] Antioxidants Examples of the antioxidant include phosphorus-based antioxidants, sulfur-based antioxidants, and phenol-based antioxidants.

[0073] The content of the antioxidant is preferably 0.1 to 10 parts by mass, more preferably 0.3 to 5 parts by mass, and even more preferably 0.5 to 3.0 parts by mass, per 100 parts by mass of the cured product.

[0074] <Light stabilizer> Examples of light stabilizers include aromatic compounds, amine compounds, organic acid compounds, catechin compounds, and hindered amine compounds, among which hindered amine compounds are preferred. Hindered amine compounds have a structure containing a 2,2,6,6-tetramethylpiperidine skeleton in the molecule.

[0075] The content of the light stabilizer is preferably 0.1 to 10 parts by mass, more preferably 0.3 to 8.0 parts by mass, and even more preferably 1.0 to 5.0 parts by mass, per 100 parts by mass of the cured product. Note that it is preferable to include a hindered amine compound as the light stabilizer in the above range.

[0076] <Ultraviolet absorber> Examples of the ultraviolet absorber include benzotriazole-based ultraviolet absorbers, benzophenone-based ultraviolet absorbers, and triazine-based ultraviolet absorbers, with triazine-based ultraviolet absorbers being preferred. One or more types of ultraviolet absorbers can be used.

[0077] Among the triazine-based ultraviolet absorbers, hydroxyphenyltriazine-based ultraviolet absorbers in which three organic groups selected from hydroxyphenyl groups, alkoxyphenyl groups, and organic groups containing these groups are linked to a triazine ring are more preferred, and hydroxyphenyltriazine-based ultraviolet absorbers represented by the following general formula (A) are even more preferred. Because the hydroxyphenyltriazine-based ultraviolet absorber has a branched structure, it is expected to be less likely to bleed out from the cured product layer, and to achieve excellent weather resistance over a longer period of time.

[0078] Furthermore, ultraviolet absorbers having an ethylenic double bond, such as a (meth)acryloyl group, a vinyl group, or an allyl group, are preferred because they are more likely to suppress bleeding out.

[0079] [ka]

[0080] In general formula (A), R 11 is a divalent organic group, and R 12 is -C(=O)OR 15 and R 13 , R 14 and R 15 are each independently a monovalent organic group, and n 11 and n 12 are each independently an integer of 1 to 5.

[0081] R 11 Examples of the divalent organic group include aliphatic hydrocarbon groups such as alkylene groups and alkenylene groups, and from the viewpoint of weather resistance, alkylene groups are preferred, and the number of carbon atoms therein is preferably 1 to 20, more preferably 1 to 12, still more preferably 1 to 8, and particularly preferably 1 to 4. The alkylene group and alkenylene group may be linear, branched, or cyclic, but linear or branched groups are preferred.

[0082] Examples of alkylene groups having 1 to 20 carbon atoms include methylene, 1,1-ethylene, 1,2-ethylene, 1,3-propylene, 1,2-propylene, 2,2-propylene, and other various propylene groups (hereinafter, "various" refers to linear, branched, and isomeric forms thereof), various butylene groups, various pentylene groups, various hexylene groups, various heptylene groups, various octylene groups, various nonylene groups, various decylene groups, various undecylene groups, various dodecylene groups, various tridecylene groups, various tetradecylene groups, various pentadecylene groups, various hexadecylene groups, various heptadecylene groups, various octadecylene groups, various nonadecylene groups, and various icosylene groups.

[0083] R 13 and R 14 Examples of the monovalent organic group include an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, and an arylalkyl group. Of these, aromatic hydrocarbon groups such as an aryl group and an arylalkyl group are preferred, and an aryl group is more preferred. 13 and R 14 The monovalent organic group is preferably a phenyl group.

[0084] The aryl group preferably has 6 to 20 carbon atoms, more preferably 6 to 12 carbon atoms, and even more preferably 6 to 10 carbon atoms, such as a phenyl group, various methylphenyl groups, various ethylphenyl groups, various dimethylphenyl groups, various propylphenyl groups, various trimethylphenyl groups, various butylphenyl groups, and various naphthyl groups. The arylalkyl group preferably has 7 to 20 carbon atoms, more preferably 7 to 12 carbon atoms, and even more preferably 7 to 10 carbon atoms, such as a benzyl group, a phenethyl group, various phenylpropyl groups, various phenylbutyl groups, various methylbenzyl groups, various ethylbenzyl groups, various propylbenzyl groups, various butylbenzyl groups, and various hexylbenzyl groups.

[0085] R 15Examples of the monovalent organic group include an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, and an arylalkyl group. Of these, an aliphatic hydrocarbon group such as an alkyl group or an alkenyl group is preferred, and an alkyl group is more preferred. That is, R 12 As the alkyl ester group, an alkyl ester group or an alkenyl ester group is preferred, and an alkyl ester group is more preferred.

[0086] The alkyl group is preferably an alkyl group having 1 to 20 carbon atoms, more preferably 2 to 16 carbon atoms, and even more preferably 6 to 12 carbon atoms, such as a methyl group, an ethyl group, various propyl groups, various butyl groups, various pentyl groups, various hexyl groups, various octyl groups, various nonyl groups, various decyl groups, various undecyl groups, various dodecyl groups, various tridecyl groups, various tetradecyl groups, various pentadecyl groups, various hexadecyl groups, various heptadecyl groups, various octadecyl groups, various nonadecyl groups, and various icosyl groups.

[0087] The alkenyl group is preferably an alkenyl group having 2 to 20 carbon atoms, more preferably 3 to 16 carbon atoms, and even more preferably 6 to 12 carbon atoms, such as a vinyl group, various propenyl groups, various butenyl groups, various pentenyl groups, various hexenyl groups, various octenyl groups, various nonenyl groups, various decenyl groups, various undecenyl groups, various dodecenyl groups, various tridecenyl groups, various tetradecenyl groups, various pentadecenyl groups, various hexadecenyl groups, various heptadecenyl groups, various octadecenyl groups, various nonadecenyl groups, and various icosenyl groups.

[0088] More specifically, the hydroxyphenyltriazine compound represented by the general formula (A) is R 11 is an alkylene group having 1 to 20 carbon atoms, and R 12 and R 15 is an alkyl ester group which is an alkyl group having 1 to 20 carbon atoms, and R 13 and R 14 is an aryl group having 6 to 20 carbon atoms, and n 11 and n 12 Hydroxyphenyltriazine compounds having a value of 1 are preferred, and R11 is an alkylene group having 1 to 12 carbon atoms, and R 12 and R 15 is an alkyl ester group having 2 to 16 carbon atoms, and R 13 and R 14 is an aryl group having 6 to 12 carbon atoms, and n 11 and n 12 Hydroxyphenyltriazine compounds in which R is 1 are more preferred, 11 is an alkylene group having 1 to 8 carbon atoms, and R 12 R 15 and an alkyl ester group, which is an alkyl group having 6 to 12 carbon atoms, R 13 and R 14 is an aryl group having 6 to 10 carbon atoms, and n 11 and n 12 More preferred are hydroxyphenyltriazine compounds in which R 11 is an alkylene group having 1 to 4 carbon atoms, and R 12 and R 15 is an ester group which is an alkyl group having 8 carbon atoms, and R 13 and R 14 is a phenyl group, and n 11 and n 12 Hydroxyphenyltriazine compounds having a molar ratio of 1 are particularly preferred.

[0089] The content of the ultraviolet absorber is preferably 0.2 to 10.0 parts by mass, more preferably 0.5 to 5.0 parts by mass, and even more preferably 1.0 to 4.0 parts by mass, per 100 parts by mass of the cured product.

[0090] 《Extender pigment》 Examples of the extender pigment include inorganic particles and / or organic particles. The extender pigment can be added for the purpose of adjusting the design of the antiviral article, or for the purpose of imparting scratch resistance, abrasion resistance, etc.

[0091] Examples of inorganic particles include silica, alumina, silicon carbide, silicon nitride, boron nitride, calcium titanate, barium titanate, magnesium pyroborate, zinc oxide, zirconium oxide, chromium oxide, iron oxide, diamond, emery, glass fiber, calcium carbonate, aluminosilicate, barium sulfate, etc. Examples of organic particles include polyethylene, urethane resin, polycarbonate, polyamide (nylon), etc.

[0092] <Antibacterial agent> Antibacterial agents include inorganic and organic antibacterial agents. In particular, inorganic antibacterial agents are desirable because they are generally safer than organic antibacterial agents and have excellent durability and heat resistance. Inorganic antibacterial agents are antibacterial metals such as silver, copper, and zinc supported on various inorganic carriers. The content of the antibacterial agent is preferably 0.1 to 10 parts by mass per 100 parts by mass of the cured product, but the details can be adjusted appropriately depending on the type of antibacterial agent.

[0093] <Anti-allergen> The antiallergen agent contains either an inorganic compound or an organic compound, and may be used alone or in combination of two or more different compounds. The inorganic compound is preferably a metal-supported material. The content of the antiallergen agent is preferably 0.1 to 10 parts by mass per 100 parts by mass of the cured product, but the content can be adjusted appropriately depending on the type of antiallergen agent.

[0094] As the inorganic material of the inorganic compound, for example, at least one selected from the group consisting of titanium oxide, calcium phosphate, calcium silicate, zirconium phosphate, zeolite, silica alumina, magnesium silicate, and magnesium phosphate is preferred, and among these, titanium oxide, zirconium phosphate, etc. are preferred.

[0095] The metal supported on the inorganic material is preferably at least one selected from the group consisting of gold, silver, platinum, zinc, and copper, and among these, silver, zinc, etc. Commercially available products that can be suitably used include, for example, "Parafine ANV-100: inorganic compound supported with silver" manufactured by Ohara Palladium Co., Ltd. and "Atomy Ball TZ-R: titanium oxide supported with zinc" manufactured by JGC Catalysts Co., Ltd. These anti-allergen agents are effective against various allergens such as dust mites and pollen.

[0096] The organic compound is preferably a water-insoluble polymer containing a phenolic hydroxyl group, a polyphenol compound supported on an inorganic solid acid, or a polymer containing at least one monomer component selected from the group consisting of styrenesulfonic acid and salts thereof.

[0097] As a water-insoluble polymer containing a phenolic hydroxyl group, commercially available products such as "Allerbuster (trade name)" manufactured by Sekisui Chemical Co., Ltd. and "Marukalinker M (trade name)" manufactured by Maruzen Oil Co., Ltd. can be used. Furthermore, an example of a combination of a polyphenol compound and a zirconium compound is "Allerremove (trade name)" manufactured by Toagosei Co., Ltd. These antiallergen agents are effective against various allergens such as dust mites and pollen.

[0098] As the at least one monomer component selected from the group consisting of styrenesulfonic acid and its salts, materials such as those disclosed in Japanese Patent No. 6136433 can be used.

[0099] In addition, when an organic compound and an inorganic compound are mixed, for example, an anionic phenolic compound and a zinc-based material having antiallergenic properties can be used.

[0100] The anionic phenolic material may be appropriately selected from tannin, tannic acid-tartar emetic, phenolsulfonic acid formaldehyde resin, sulfone compounds of novolak resins, methanesulfonic acid of novolak resins, methanesulfonic acid of resol resins, benzylated phenolsulfonic acid, thiophenol compounds, dihydroxydiphenylsulfone compounds, ligand compounds, and metal chelate compounds thereof.

[0101] The zinc-based material is suitably selected from a water-soluble zinc compound or a water-insoluble zinc compound, a zinc / metal oxide composite material, etc., and it is preferable that the water-insoluble zinc compound and / or water-insoluble zinc-metal oxide composite particles are dispersed in water, have a particle diameter of 50 μm or less, and the metal oxide contains at least one of titania, silica, and alumina.

[0102] <Thickness> From the viewpoint of a balance between processing characteristics and scratch resistance, the thickness of the cured product layer is preferably from 1.5 μm to 30 μm, more preferably from 2 μm to 20 μm, and even more preferably from 3 μm to 15 μm.

[0103] <Formation method> The cured material layer can be formed, for example, by applying, drying, and curing an ink for the cured material layer, which contains materials constituting the cured material layer (such as a curable resin composition and antiviral particles) and a solvent added as necessary, onto a substrate. The cured material layer can also be formed by applying, drying, and curing the ink for the cured material layer onto a substrate having releasability to form a cured material layer, and then transferring the cured material layer to another substrate, etc.

[0104] As described above, by applying an ink for the cured material layer, which contains materials that constitute the cured material layer (such as a curable resin composition and antiviral particles) and a solvent, to a substrate, followed by drying and curing, to form a cured material layer, the antiviral particles can be made to float more easily to the surface of the cured material layer when the solvent evaporates, making it easier to distribute the antiviral particles unevenly near the surface of the cured material layer.

[0105] <Layer structure> The antiviral article of the present invention may be a single layer of the cured product layer, or may have layers other than the cured product layer.

[0106] An antiviral article consisting of a single layer of a cured material layer can be obtained, for example, by producing a laminate by forming a cured material layer on a substrate having releasability, and then peeling off the substrate having releasability from the laminate.

[0107] Examples of layers other than the cured product layer that the antiviral article has include a substrate, a primer layer, a decorative layer, a transparent resin layer, an adhesive layer, etc. Examples of layer configurations of antiviral articles include the following (1) to (12). In the following (1) to (12), " / " indicates the interface between each layer.

[0108] Examples of layers other than the cured layer that the antiviral article may have include functional layers such as a magnetic layer for magnetic recording, a conductive layer that functions as a circuit, copper wire for current, or electromagnetic wave shielding layer, a gas barrier layer that suppresses the transmission of gases such as water vapor and oxygen, a light-reflecting layer that reflects visible light with high reflectance, and an antireflection layer that suppresses reflection of visible light. These functional layers can be formed in any of the following laminate structures (1) to (12) depending on the function of each layer. (1) Cured material layer (2) Base material / cured material layer (3) Substrate / Primer layer / Cured material layer (4) Base material / decorative layer / hardened material layer (5) Base material / transparent resin layer / cured material layer (6) Base material / adhesive layer / transparent resin layer / cured material layer (7) Base material / adhesive layer / decorative layer / transparent resin layer / cured material layer (8) Base material / decorative layer / adhesive layer / transparent resin layer / cured material layer (9) Substrate / Transparent Resin Layer / Primer Layer / Cured Material Layer (10) Substrate / Adhesive Layer / Transparent Resin Layer / Primer Layer / Cured Material Layer (11) Substrate / Adhesive Layer / Decorative Layer / Transparent Resin Layer / Primer Layer / Cured Material Layer (12) Base material / decorative layer / adhesive layer / transparent resin layer / primer layer / cured material layer In the above laminated structure, the adhesive layer may be any pressure-sensitive adhesive layer. Also, an adhesive layer or pressure-sensitive adhesive layer may be further provided on the back surface of the substrate.

[0109] From the viewpoint of ease of handling, the antiviral article preferably has a configuration in which a cured product layer is provided on a substrate.

[0110] 《Base material》 The form of the substrate is not particularly limited, and may include flat shapes such as films, sheets, and plates, as well as three-dimensional shapes such as polyhedrons, polygonal prisms, cylinders, spheres, and spheroids.

[0111] Although films, sheets, and plates are often referred to as films, sheets, and plates in the order of relatively thinnest thickness, no distinction is made between these three in this specification unless otherwise specified.

[0112] Examples of materials constituting the substrate include resins, metals, non-metallic inorganic materials, fibrous materials, and wood-based materials, and can be appropriately selected depending on the application.

[0113] The substrate may be a single layer, or may be a laminate of two or more layers made of the above materials. When the substrate is a laminate of two or more layers, it is preferable that two or more layers of different materials are laminated so that the properties of the materials in each layer complement each other. Examples of substrates made of two or more layers are A to J below. Note that " / " indicates the interface between each layer. (A) Resin / wood material (B) Resin / metal (C) Resin / fibrous materials (D) Resin / nonmetallic inorganic material (E) Resin 1 / Resin 2 (F) Metal / wood materials (G) Metal / non-metallic inorganic materials (H) Metal / fibrous materials (I) Metal 1 / Metal 2 (J) Non-metallic inorganic materials / fibrous materials

[0114] In the above E, resin 1 and resin 2 represent different types of resins (for example, resin 1 is an olefin resin and resin 2 is an acrylic resin). Also, in the above H, metal 1 and metal 2 represent different types of metals (for example, metal 1 is copper and metal 2 is chromium).

[0115] Furthermore, when the substrate is a laminate such as those A to J above, a layer (adhesive layer or the like) for strengthening adhesive strength may be provided between the constituent layers of the laminate.

[0116] Resins used as the substrate include various synthetic resins and natural resins, including thermoplastic resins and curable resins.

[0117] Examples of thermoplastic resins include olefin resins such as polyethylene, polypropylene, polymethylpentene, ionomers, and various olefin-based thermoplastic elastomers; vinyl chloride resins such as polyvinyl chloride, polyvinylidene chloride, and vinyl chloride-vinyl acetate copolymers; polyester resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, ethylene glycol-terephthalic acid-isophthalic acid copolymers, and polyester-based thermoplastic elastomers; acrylic resins such as polymethyl (meth)acrylate, polyethyl (meth)acrylate, polybutyl (meth)acrylate, and methyl (meth)acrylate-butyl (meth)acrylate copolymers; polyamide resins typified by nylon 6 or nylon 66; cellulose resins such as cellulose triacetate, cellophane, and celluloid; styrene resins such as polystyrene, acrylonitrile-styrene copolymers, and acrylonitrile-butadiene-styrene copolymers (ABS); polyvinyl alcohol, ethylene-vinyl acetate copolymers, ethylene-vinyl alcohol copolymers, polycarbonate resins, polyarylate resins, and polyimide resins.

[0118] Examples of the curable resin include the thermosetting resins and / or ionizing radiation curable resins exemplified for the cured material layer.

[0119] Natural resins include natural rubber, pine resin, and amber.

[0120] Examples of metals that can be used as the substrate include aluminum or aluminum-containing alloys such as duralumin, iron or iron-containing alloys such as carbon steel and stainless steel, copper or copper-containing alloys such as brass and bronze, gold, silver, chromium, nickel, cobalt, tin, titanium, etc. Metal substrates that have been plated with these metals or the like can also be used.

[0121] Examples of non-metallic inorganic materials used as the substrate include non-ceramic ceramic materials such as cement, ALC (aerated lightweight concrete), gypsum, calcium silicate, and wood chip cement; ceramic ceramic materials such as porcelain, earthenware, glass, and enamel; and natural stones such as limestone (including marble), granite, and andesite.

[0122] Examples of fibrous materials used as substrates include tissue paper, kraft paper, wood-free paper, Japanese paper, titanium paper, linter paper, parchment paper, parchment paper, glassine paper, wallpaper backing paper, paperboard and gypsum board base paper, and other papers; woven or nonwoven fabrics made of fibers such as polyester resin fiber, acrylic resin fiber, protein-based or cellulose-based natural fibers such as silk, cotton, and hemp; glass fiber; and carbon fiber. These papers may further contain resins such as acrylic resin, styrene-butadiene rubber, melamine resin, and urethane resin (impregnated after papermaking or inserted during papermaking) to increase the strength between the fibers of the paper substrate or between other layers of the paper and to prevent fluffing. Examples of resin-added papers include inter-fiber reinforced paper and resin-impregnated paper.

[0123] Furthermore, an example of a substrate in which a resin layer is laminated onto a fibrous material layer is wallpaper base paper, which is often used in the building materials field and has a resin layer such as a vinyl chloride resin layer, an olefin resin layer, or an acrylic resin layer laminated on the surface of wallpaper backing paper.

[0124] The shape and dimensions of the substrate are not particularly limited and may be appropriately selected depending on the intended use, desired performance properties and processability.

[0125] When the substrate is a flat film, sheet, or plate, the thickness is a typical dimension in the design of the article. There are no particular restrictions on the thickness, but it is generally set to about 10 μm or more and 10 cm or less from the viewpoints of manufacturing processability, mechanical strength, ease of use and handling, and economic efficiency. In the case of a film or sheet, a thickness of about 20 μm or more and 300 μm or less is usually selected, and in the case of a plate, a thickness of about 1 mm or more and 2 cm or less is usually selected.

[0126] To improve adhesion between the substrate and other layers constituting the antiviral article or between the antiviral article and a member to be laminated thereto, one or both surfaces of the substrate can be subjected to a surface treatment such as a physical surface treatment by an oxidation method or a roughening method, or a chemical surface treatment.

[0127] Examples of oxidation methods include corona discharge treatment, chromium oxidation treatment, flame treatment, hot air treatment, ozone-ultraviolet treatment, etc., and examples of roughening methods include sandblasting, solvent treatment, etc. These surface treatments are appropriately selected depending on the type of substrate, but corona discharge treatment is generally preferred in terms of the effect of the surface treatment and operability.

[0128] <Primer layer> The antiviral article preferably has a primer layer in contact with the substrate-side surface of the cured material layer. The primer layer improves adhesion between the substrate and the cured material layer, making it easier to ensure long-term interlayer adhesion when exposed to ultraviolet light (so-called weather-resistant adhesion) and improve scratch resistance.

[0129] The primer layer is mainly composed of a binder resin, and may contain additives such as an ultraviolet absorber and a light stabilizer, if necessary.

[0130] Preferred examples of binder resins include urethane resins, acrylic polyol resins, acrylic resins, ester resins, amide resins, butyral resins, styrene resins, urethane-acrylic copolymers, polycarbonate-based urethane-acrylic copolymers (urethane-acrylic copolymers derived from polymers (polycarbonate polyols) having carbonate bonds in the polymer main chain and two or more hydroxyl groups at the terminals and side chains), vinyl chloride-vinyl acetate copolymer resins, vinyl chloride-vinyl acetate-acrylic copolymer resins, chlorinated propylene resins, nitrocellulose resins (nitrocellulose), and cellulose acetate resins. These may be used alone or in combination. Furthermore, the binder resin may be a resin obtained by adding a curing agent such as an isocyanate-based curing agent or an epoxy-based curing agent to the resin and crosslinking and curing the resin. Among these, a polyol-based resin such as an acrylic polyol resin is preferably crosslinked and cured with an isocyanate-based curing agent, and an acrylic polyol resin is more preferably crosslinked and cured with an isocyanate-based curing agent.

[0131] The primer layer preferably contains an ultraviolet absorber and / or a light stabilizer to further improve weather resistance. General-purpose ultraviolet absorbers and light stabilizers can be used.

[0132] The thickness of the primer layer is preferably 0.01 μm or more and 10 μm or less, more preferably 0.7 μm or more and 8 μm or less, and even more preferably 1.0 μm or more and 6 μm or less.

[0133] The antiviral article may have a back primer layer on the side of the substrate opposite the cured product layer for the purpose of improving adhesion to an adherend, etc.

[0134] The antiviral article may also have a pressure-sensitive adhesive layer on the side of the substrate opposite the cured layer for the purpose of bonding to an adherend. It is preferable to form a peelable separator on the surface of the pressure-sensitive adhesive layer opposite the substrate.

[0135] 《Transparent resin layer》 The antiviral article may have a transparent resin layer between the substrate and the cured product layer from the viewpoint of increasing strength, etc. In particular, when the substrate is a resin substrate, it is preferable that the antiviral article have a transparent resin layer.

[0136] When the antiviral article has a primer layer, the transparent resin layer is preferably located between the substrate and the primer layer. When the antiviral article has a decorative layer, the transparent resin layer is preferably located between the decorative layer and the cured product layer from the viewpoint of protecting the decorative layer.

[0137] Examples of resins constituting the transparent resin layer include polyolefin resins, polyester resins, polycarbonate resins, acrylonitrile-butadiene-styrene resins (hereinafter also referred to as "ABS resins"), acrylic resins, vinyl chloride resins, etc. Among these, polyolefin resins are preferred from the viewpoint of processability. Furthermore, two or more of these exemplified resins may be laminated or mixed for use.

[0138] From the viewpoint of processability, the content of polyolefin resin in the transparent resin layer is preferably 50% by mass or more, more preferably 70% by mass or more, and even more preferably 90% by mass or more, of the total resin components of the transparent resin layer.

[0139] Examples of polyolefin resins for the transparent resin layer include polyethylene (low density, medium density, high density), polypropylene, polymethylpentene, polybutene, ethylene-propylene copolymer, propylene-butene copolymer, ethylene-vinyl acetate copolymer, ethylene-acrylic acid copolymer, ethylene-propylene-butene copolymer, etc. Among these, polyethylene (low density, medium density, high density), polypropylene, ethylene-propylene copolymer, and propylene-butene copolymer are preferred, and polypropylene is more preferred.

[0140] The transparent resin layer may contain additives such as an ultraviolet absorber, a light stabilizer, and a colorant.

[0141] The thickness of the transparent resin layer is preferably from 20 μm to 150 μm, more preferably from 40 μm to 120 μm, and even more preferably from 60 μm to 100 μm, from the viewpoint of a balance between scratch resistance, processability, and weather resistance.

[0142] Decorative Layer From the viewpoint of improving the design, the antiviral article preferably has a decorative layer at any location on the antiviral article.

[0143] From the viewpoint of improving the weather resistance of the decorative layer, the decorative layer is preferably formed on a side closer to the substrate. For example, when the antiviral article has a primer layer, the decorative layer is preferably located between the substrate and the primer layer. Furthermore, when the antiviral article has a transparent resin layer, the decorative layer is preferably located between the substrate and the transparent resin layer.

[0144] The decorative layer may be formed on the entire surface of the antiviral article, or may be formed only on a part of it. When the decorative layer covers the outer surface of the cured material layer, it is preferable to form the decorative layer only on a partial region so as not to inhibit the expression of the antiviral properties.

[0145] Examples of the decorative layer include a colored layer formed by applying ink in a solid manner, a patterned layer formed by printing ink as a pattern, and a thin metal film.

[0146] Examples of patterns (designs) that can be expressed by the decorative layer include wood grain patterns such as tree rings and vessel grooves on the surface of wooden boards; stone grain patterns on the surface of stone slabs such as marble and granite; fabric grain patterns on the surface of fabric; leather grain patterns on the surface of leather; tile patterns including grooves; brickwork patterns including grooves; sand grain patterns; pear-skin patterns; patterns consisting of an arrangement of multiple concave and convex stripes extending in parallel directions (so-called ``line-like concave and convex patterns'' or ``ray-carved patterns''); and abstract patterns such as geometric patterns, letters, figures, polka dots, and floral designs.

[0147] The ink used for the colored layer and the design layer is a mixture of a binder resin with an appropriate amount of a colorant such as a pigment or dye, an extender pigment, a solvent, a stabilizer, a plasticizer, a catalyst, a curing agent, an ultraviolet absorber, a light stabilizer, etc.

[0148] The binder resin for the colored layer and the design layer is not particularly limited, and examples thereof include urethane resin, acrylic polyol resin, acrylic resin, ester resin, amide resin, butyral resin, styrene resin, urethane-acrylic copolymer, vinyl chloride-vinyl acetate copolymer resin, vinyl chloride-vinyl acetate-acrylic copolymer resin, chlorinated propylene resin, nitrocellulose resin, cellulose acetate resin, etc. In addition, various types of resins can be used, such as one-component curing resins and two-component curing resins containing a curing agent such as an isocyanate compound.

[0149] The colorant is not particularly limited, and examples thereof include inorganic pigments such as carbon black (ink), iron black, titanium white, antimony white, yellow lead, titanium yellow, red iron oxide, cadmium red, ultramarine blue, and cobalt blue; organic pigments or dyes such as quinacridone red, isoindolinone yellow, nickel azo complex, phthalocyanine blue, and azomethine azo black; metal pigments consisting of flaky flakes of aluminum, brass, or the like; and pearlescent pigments consisting of flaky flakes of titanium dioxide-coated mica, basic lead carbonate, or the like.

[0150] The content of the colorant is preferably 5 parts by mass or more and 90 parts by mass or less, more preferably 15 parts by mass or more and 80 parts by mass or less, and even more preferably 30 parts by mass or more and 70 parts by mass or less, relative to 100 parts by mass of the resin constituting the colored layer and the pattern layer.

[0151] The color layer and the design layer may contain additives such as ultraviolet absorbers, light stabilizers, and colorants.

[0152] The thickness of the colored layer and the patterned layer may be selected appropriately depending on the desired pattern, but from the viewpoint of concealing the base color of the adherend and improving the design, it is preferably 0.5 μm or more and 20 μm or less, more preferably 1 μm or more and 10 μm or less, and even more preferably 2 μm or more and 5 μm or less.

[0153] Examples of metal thin films include thin films of simple metal elements such as gold, silver, copper, tin, iron, nickel, chromium, cobalt, indium, and aluminum, and thin films of alloys containing two or more of the above metal elements. Examples of alloys include brass, bronze, and stainless steel.

[0154] The metal thin film can have a thickness of about 0.1 μm to 1 μm.

[0155] 《Adhesive layer》 The antiviral article may have an adhesive layer.

[0156] For example, when the antiviral article has a transparent resin layer, it is preferable to form an adhesive layer between the substrate and the transparent resin layer in order to improve the adhesion between the two layers.

[0157] When a decorative layer is further provided between the substrate and the transparent resin layer, the positional relationship between the adhesive layer and the decorative layer is not particularly limited. Specifically, the decorative layer, adhesive layer, and transparent resin layer may be provided in this order from the side closest to the substrate, or the adhesive layer, decorative layer, and transparent resin layer may be provided in this order from the side closest to the substrate layer.

[0158] Furthermore, as described above, when the substrate is a laminate of two or more layers, an adhesive layer may be provided between the layers constituting the substrate.

[0159] The adhesive layer can be made of, for example, an adhesive such as a urethane adhesive, an acrylic adhesive, an epoxy adhesive, a rubber adhesive, etc. Among these adhesives, a urethane adhesive is preferred in terms of adhesive strength.

[0160] Examples of urethane adhesives include adhesives that utilize two-component curing urethane resins containing various polyol compounds such as polyether polyol, polyester polyol, and acrylic polyol, and a curing agent such as an isocyanate compound.

[0161] The thickness of the adhesive layer is preferably 0.1 μm or more and 30 μm or less, more preferably 1 μm or more and 15 μm or less, and even more preferably 2 μm or more and 10 μm or less.

[0162] The decorative layer, adhesive layer, and primer layer described above can be formed by applying a coating liquid containing a composition for forming each layer by a known method such as gravure printing, bar coating, roll coating, reverse roll coating, or comma coating, and then drying and curing the coating as necessary.

[0163] <Forming processing> The antiviral article may be given a desired uneven shape (also called an uneven pattern) by a shaping treatment such as embossing.

[0164] When embossing is performed, for example, the antiviral article is heated to preferably from 80°C to 260°C, more preferably from 85°C to 200°C, and even more preferably from 100°C to 180°C, and then an embossing plate is pressed against the antiviral article. The area where the embossing plate is pressed is preferably the cured product layer side of the antiviral article.

[0165] <Application> The antiviral article of the present invention can be used for various purposes, including the following (1) to (12): (1) Surface materials for interior walls, floors, ceilings, etc. of buildings such as houses, offices, stores, hospitals, and clinics. (2) Surface materials for exterior parts such as exterior walls, roofs, eaves ceilings, door pockets, etc. of buildings such as houses, offices, stores, hospitals, and clinics. (3) Surface materials for building fixtures such as windows, window frames, doors, and door frames (interior or exterior parts); surface materials for fixture accessories (handles, etc.); surface materials for building fixture jigs. (4) Surface materials for fixtures such as handrails, waist walls, moldings, thresholds, lintels, and top boards. (5) Surface materials for outdoor (exterior) parts such as fences, gates, drying rack pillars and handrails. (6) Surface materials for furniture such as chests of drawers, desks, chairs, cupboards, kitchen sinks, etc.; surface materials for furniture accessories (handles, etc.); surface materials for furniture fixtures. (7) Surface materials for the housings of various home appliances such as television receivers, radio receivers, refrigerators, microwave ovens, washing machines, electric fans, and air conditioners; surface materials for accessories of home appliances (handles, switches, touch panels, etc.); surface materials for fixtures of home appliances. (8) Surface materials for office automation equipment such as electronic copying machines, facsimiles, printers, personal computers, and other computing equipment; surface materials for the housings of various office automation equipment such as ATM machines at financial institutions such as banks and post offices; surface materials for accessories of various office automation equipment (keyboards, touch panels, etc.); surface materials for jigs of various office automation equipment. (9) Surface materials for the interior or exterior parts (walls, floors, ceilings, handrails, supports, control panels, levers, handles, steering wheels, and other control equipment) of vehicles such as automobiles, railway cars, ships, and aircraft. (10) Partitions in various buildings; shielding plates or curtains to prevent droplet infection of viruses at counters, accounting counters, etc. of stores, offices, government offices, etc.; face protection equipment such as protective masks (face guards) and protective glasses (goggles); or surface materials for these. (11) Business forms such as slips; bankbooks; cards such as cash cards, credit cards, and point cards of financial institutions; or the surface materials of these. (12) Glass, resin, etc. bottles; metal cans; resin soft packaging materials such as resin retort containers; packaging materials such as various tubes; or the surface materials of these.

[0166] <Vesiculation of various additives contained in each layer of antiviral articles> As described above, the antiviral article of the present invention may be a single layer of the cured material layer, or may have layers other than the cured material layer, but it is preferable that the various additives added to each layer are vesiculated. The method for vesiculating the various additives is not particularly limited, and they can be vesiculated by any known method, among which supercritical reverse phase evaporation is preferred.

[0167] In addition to supercritical reverse-phase evaporation, other vesicle-forming methods include the Bangham method, extrusion, hydration, reverse-phase evaporation, and freeze-thaw. Briefly, the Bangham method involves dissolving phospholipids in chloroform or a chloroform / methanol mixture in a flask or other container. The solvent is then removed using an evaporator to form a thin lipid film. A dispersion of additives is then added, followed by hydration and dispersion in a vortex mixer to obtain vesicles. The extrusion method involves preparing a thin phospholipid solution and passing it through a filter, replacing the mixer used as an external perturbation in the Bangham method, to obtain vesicles. The hydration method is similar to the Bangham method, but does not require a mixer. Instead, vesicles are obtained by gentle agitation and dispersion. The reverse phase evaporation method involves dissolving phospholipids in diethyl ether or chloroform, adding a solution containing an additive, creating a W / O emulsion, removing the organic solvent from the emulsion under reduced pressure, and then adding water to obtain vesicles. The freeze-thaw method uses cooling and heating as an external perturbation, and vesicles are obtained by repeating this cooling and heating process.

[0168] The supercritical reverse-phase evaporation method is described in detail below. Supercritical reverse-phase evaporation is a method in which a substance forming the outer membrane of a vesicle is uniformly dissolved in carbon dioxide in a supercritical state or at a temperature or pressure above the supercritical point. An aqueous phase containing various water-soluble or hydrophilic additives as encapsulated substances is added to the mixture to form a capsule-like vesicle encapsulating the various additives as encapsulated substances in a single layer. Note that "supercritical carbon dioxide" refers to carbon dioxide in a supercritical state above its critical temperature (30.98°C) and critical pressure (7.3773±0.0030 MPa). "Carbon dioxide at a temperature or pressure above its critical point" refers to carbon dioxide under conditions where only the critical temperature or only the critical pressure exceeds the critical condition. This method can produce unilamellar vesicles with diameters of 50 to 800 nm. Generally, a vesicle is a collective term for a small vesicle with a spherical, closed membrane structure that contains a liquid phase inside. In particular, liposomes are those whose outer membrane is composed of biological lipids such as phospholipids.

[0169] Examples of the phospholipids include glycerophospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, cardiolipin, egg yolk lecithin, hydrogenated egg yolk lecithin, soybean lecithin, and hydrogenated soybean lecithin; and sphingophospholipids such as sphingomyelin, ceramide phosphorylethanolamine, and ceramide phosphorylglycerol.

[0170] The substance that can be used to form the outer membrane may also be a dispersant such as a nonionic surfactant or a mixture of a nonionic surfactant with cholesterol or triacylglycerol.

[0171] As the nonionic surfactant, one or more of polyglycerin ether, dialkylglycerin, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester, polyoxyethylene polyoxypropylene copolymer, polybutadiene-polyoxyethylene copolymer, polybutadiene-poly2-vinylpyridine, polystyrene-polyacrylic acid copolymer, polyethylene oxide-polyethylethylene copolymer, polyoxyethylene-polycaprolactam copolymer, etc. can be used.

[0172] As the cholesterols, one or more of cholesterol, α-cholestanol, β-cholestanol, cholestane, desmosterol (5,24-cholestadien-3β-ol), sodium cholate, cholecalciferol, and the like can be used.

[0173] The outer membrane of the liposome may be formed from a mixture of a phospholipid and a dispersant. In the decorative sheet of the present invention, by using a liposome whose outer membrane is formed from a phospholipid, it is possible to improve the compatibility between the resin composition, which is the main component of each layer, and various additives.

[0174] [Antiviral resin composition] The antiviral resin composition of the present invention contains a curable resin composition and antiviral particles.

[0175] The embodiments of the "curable resin composition" and "antiviral particles" in the antiviral resin composition of the present invention are the same as the embodiments of the "curable resin composition" and "antiviral particles" in the antiviral article of the present invention described above.

[0176] The antiviral resin composition of the present invention may contain additives, such as a phenyl ether derivative compound, an antioxidant, a light stabilizer, an ultraviolet absorber, an extender pigment (inorganic particles or organic particles), an antibacterial agent, an antiallergen, an antifungal agent, a flame retardant, a lubricant, a foaming agent, or a deodorizer, as necessary.

[0177] The embodiments of the "phenyl ether derivative compound," "antioxidant," "light stabilizer," "ultraviolet absorber," "extender pigment (inorganic particles, organic particles)," "antibacterial agent," and "antiallergen" in the antiviral resin composition of the present invention are the same as the embodiments of the "antioxidant," "light stabilizer," "ultraviolet absorber," "extender pigment (inorganic particles, organic particles)," "antibacterial agent," and "antiallergen" in the antiviral article of the present invention described above.

[0178] <Solvent> The antiviral resin composition of the present invention preferably contains a solvent. When the antiviral resin composition contains a solvent, the antiviral particles can be more likely to float to the surface of the cured material layer when the solvent volatilizes, and the antiviral particles can be more likely to be unevenly distributed near the surface of the cured material layer.

[0179] Examples of the solvent include ketones (acetone, methyl ethyl ketone, methyl isobutyl ketone (MIBK), cyclohexanone, etc.), ethers (dioxane, tetrahydrofuran, etc.), aliphatic hydrocarbons (hexane, etc.), alicyclic hydrocarbons (cyclohexane, etc.), aromatic hydrocarbons (toluene, xylene, etc.), halogenated carbons (dichloromethane, dichloroethane, etc.), esters (methyl acetate, ethyl acetate, butyl acetate, etc.), alcohols (isopropanol, butanol, cyclohexanol, etc.), cellosolves (methyl cellosolve, ethyl cellosolve, etc.), glycol ethers (propylene glycol monomethyl ether acetate, etc.), cellosolve acetates, sulfoxides (dimethyl sulfoxide, etc.), amides (dimethylformamide, dimethylacetamide, etc.), and mixtures thereof may also be used.

[0180] Among these, for example, methyl ethyl ketone and ethyl acetate are preferred from the viewpoint of maintaining the shape of the antiviral particles.

[0181] The content of the solvent is preferably 10 to 60 mass %, and more preferably 30 to 50 mass %, of the total amount of the antiviral resin composition (ink for the cured product layer). [Example]

[0182] Next, the present invention will be described in more detail by way of examples, but the present invention is not limited to these examples in any way.

[0183] 1. Evaluation of discoloration prevention The inks for cured product layers (antiviral resin compositions) of the Examples and Comparative Examples, and the antiviral articles of the Examples and Comparative Examples were evaluated as follows. The evaluation atmosphere was a temperature of 23°C ± 5°C and a humidity of 40 to 65% RH.

[0184] 1-1. Discoloration of the ink for the cured layer (antiviral resin composition) In a room shielded from external light, 30 g of the inks for cured material layers (antiviral resin compositions) of the Examples and Comparative Examples were placed in glass bottles (manufactured by AS ONE Corporation, product number: Labolan screw cap bottle, 50 ml) and the lids were closed to prepare samples for evaluation. At this stage, the color of the inks for cured material layers (antiviral resin compositions) in the samples was white, and showed no difference from the color of compositions containing no antiviral agent (compositions obtained by removing the antiviral agent from the inks for cured material layers (antiviral resin compositions) of the Examples and Comparative Examples).

[0185] The sample was then placed on a desk and left indoors under fluorescent lighting for 24 hours, after which the color of the ink for the cured layer (antiviral resin composition) in the sample was visually evaluated. The brightness of the fluorescent lighting on the desk was set to a range of 500 to 1,000 lux. The results are shown in Table 1.

[0186] 1-2. Discoloration of antiviral products Regarding the antiviral articles of the Examples and Comparative Examples, * a * b *The measurement device used was a spectrophotometer ("Spectrolino" (model number), manufactured by GretagMacbeth).

[0187] Next, the antiviral articles of the examples and comparative examples were subjected to an accelerated weathering test using a metal halide lamp (MWOM) for 8 cycles (192 hours). (This test involved repeating a cycle consisting of 20 hours of ultraviolet irradiation under the following irradiation conditions, followed by 4 hours of condensation under the following condensation conditions.) * a * b * The values ​​were measured.

[0188] The color difference (ΔE * ab) were calculated, and the results are shown in Table 1.

[0189] Color difference (ΔE * ab) are measured values ​​immediately after production *1 , a *1 and b *1 The measured value after the accelerated weathering test is L *2 , a *2 and b *2 Then, it can be calculated using the following formula: ΔE * ab=〔(L *2 -L *1 ) 2 +(a *2 -a *1 ) 2 +(b * 2-a *2 ) 2 〕 1 / 2

[0190] <Test equipment> Product name "Daipla Metal Weather" manufactured by Daipla Wintes Co., Ltd. <Irradiation conditions> Illuminance: 65mW / cm 2 Black panel temperature: 63°C, chamber humidity: 50%RH, time: 20 hours <Condensation conditions> Illuminance: 0mW / cm2 , Humidity inside the tank: 98%RH, Time: 4 hours

[0191] 2. Preparation of ink for cured layer (antiviral resin composition) and production of antiviral article [Example 1] The following components were mixed and stirred to prepare ink a for the cured product layer (antiviral resin composition a) of Example 1.

[0192] <Ink a for cured layer (antiviral resin composition a)> ·Ionizing radiation curable resin composition 100 parts by mass (100 parts by weight of urethane acrylate resin consisting of 70 parts by weight of multifunctional urethane oligomer and 30 parts by weight of bifunctional oligomer) 5 parts by mass of antiviral particles A (containing the following particles A1 and A2 in a mass ratio of 1:1) (Particles containing a styrene polymer derivative compound (particles A1): polystyrene sulfonic acid derivative manufactured by Shima Trading Co., Ltd., product name "VERSA-TL3") (Particles containing an unsaturated carboxylic acid derivative compound (particles A2): Particles formed by drying a solvent-based unsaturated polycarboxylic acid polymer manufactured by BYK, product name "BYK-P104"

[0193] Next, a decorative layer ink containing a two-component curing acrylic-urethane resin and a colorant was applied by gravure printing to one side of a substrate (a 60 μm thick titanium oxide-containing polypropylene resin sheet) that had been subjected to corona discharge treatment on both sides, and then dried to form a 3 μm thick wood grain pattern decorative layer.

[0194] Next, a 3 μm thick adhesive layer made of a urethane resin adhesive was formed on the decorative layer, and then a polypropylene resin was hot-melt extruded onto the adhesive layer using a T-die extruder to form an 80 μm thick transparent resin layer.

[0195] Next, the surface of the transparent resin layer was subjected to a corona discharge treatment, and then the ink for the primer layer was applied onto the transparent resin layer by gravure printing and dried to form a primer layer having a thickness of 2 μm.

[0196] Next, the ink a for cured layer (antiviral resin composition a) was applied onto the primer layer by roll coating to form an uncured cured layer, which was then dried at 60°C for 1 minute and then irradiated with an electron beam (applied voltage: 125 kV, 5 Mrad (50 kGy)) to crosslink and cure the curable resin composition (ionizing radiation-curable resin composition), forming a cured layer with a thickness of 15 μm, thereby obtaining the antiviral article of Example 1.

[0197] [Comparative Example 1] An ink b for a cured material layer (antiviral resin composition b) of Comparative Example 1 was prepared by removing the antiviral particles A from the ink a for a cured material layer (antiviral resin composition a) used in Example 1 and adding, instead, 3 parts by mass of antiviral particles B (product number "AJ10N" manufactured by Sinanen Zeomic, average particle diameter 2.5 μm) obtained by supporting silver ions on zeolite.

[0198] Next, an antiviral article of Comparative Example 1 was obtained in the same manner as in Example 1, except that the ink a for cured product layer (antiviral resin composition a) was changed to the ink b for cured product layer (antiviral resin composition b).

[0199] [Table 1]

[0200] As shown in Table 1, it can be confirmed that the ink for the cured product layer (antiviral resin composition) and the antiviral article of Example 1 can suppress discoloration.

[0201] 3. Evaluation of antiviral and antiallergen properties [Example 2] An antiviral article was obtained in the same manner as in Example 1, except that in the ink a for cured product layer used in Example 1, the antiviral particles A were changed to particles containing a styrene resin (particles A3) (styrene resin particles manufactured by Polysciences, product name "Microsphere (particle diameter 4.5 μm)").

[0202] [Example 3] An antiviral article was obtained in the same manner as in Example 1, except that an anionic phenol-based material having antiallergenic properties ("EXP20530A" manufactured by DIC Corporation) and a zinc-based material having antiallergenic properties ("EXP20530B" manufactured by DIC Corporation) were blended into the ink a for the cured material layer of Example 1. The anionic phenol-based material and the zinc-based material were blended so that their solid content ratios were 23% by mass each in 100% by mass of the ink a for the cured material layer after blending.

[0203] [Example 4] An antiviral article was obtained in the same manner as in Example 1, except that in the ink a for cured product layer of Example 1, the antiviral particles A were a mixture of the particles A1, A2, and A3, and an antiviral additive: polyoxyethylene alkyl ether manufactured by Kao Chemicals, trade name "EMULGEN 707" was further blended.

[0204] The antiviral particles A contain particles A1, A2, and A3 in a mass ratio of 3:2:3. The antiviral particles A were blended in an amount of 4 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition. The content of the antiviral additive was 4 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition (the same applies to the parts by mass per 100 parts by mass of the cured product).

[0205] [Example 5] An antiviral article was obtained in the same manner as in Example 1, except that in ink a for cured product layer in Example 1, the antiviral particles A were changed to the particles A3, and an antiviral additive: polyoxyethylene alkyl ether manufactured by Kao Chemicals, product name "EMULGEN 707" was further blended.

[0206] The antiviral particles A were blended in an amount of 1.5 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition. Furthermore, the content of the antiviral additive was 3 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition (the same applies to the parts by mass per 100 parts by mass of the cured product).

[0207] [Example 6] An antiviral article was obtained in the same manner as in Example 1, except that an antiviral additive: polyoxyethylene alkyl ether manufactured by Kao Chemicals, product name "EMULGEN 707" was further blended in ink a for cured product layer in Example 1.

[0208] The antiviral particles A contained particles A1 and particles A2 in a mass ratio of 2:3. The antiviral particles A were blended in an amount of 2.5 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition. The content of the antiviral additive was 3 parts by mass per 100 parts by mass of the ionizing radiation-curable resin composition (the same applies to the parts by mass per 100 parts by mass of the cured product).

[0209] (Antiviral performance) The antiviral articles produced in Examples 1, 2, 4 to 6 and Comparative Example 1 were subjected to an antiviral performance test in accordance with the antiviral testing method (ISO21702), and the antiviral activity values ​​against the following virus species were evaluated based on the following evaluation criteria. Virus species: enveloped viruses (influenza viruses), non-enveloped viruses (feline calicivirus) ++: Antiviral activity values ​​against both virus species are 2.0 or higher +: Antiviral activity value against one virus species is 2.0 or higher -: Antiviral activity values ​​against both virus species are less than 2.0

[0210] The results are shown in Table 2.

[0211] [Table 2]

[0212] (Anti-allergen performance) The allergen performance of the antiviral articles prepared in Examples 1 and 3 was evaluated. Specifically, the antiviral articles prepared in Examples 1 and 3 were cut into small pieces and immersed in an aqueous solution of mite allergen for one day, after which the amount of allergen was visually confirmed using horizontal development chromatography (Mighty Checker) and evaluated according to the following evaluation criteria. The evaluation criteria are as follows: +: A reduction in the amount of allergens was confirmed (mite allergen level judgment was + or less (i.e., about 100 mites / m 2 below) -: No reduction in allergens was confirmed (mite allergen level judged as + or above)

[0213] The results are shown in Table 3.

[0214] [Table 3] The difference in color density of the checker confirmed that the decorative sheet of Example 3 had anti-allergen properties compared to the decorative sheet of Example 1. [Explanation of symbols]

[0215] 100: Antiviral products 10: Cured material layer 11: Cured product of curable resin composition 12: Antiviral particles 20: Base material

Claims

1. An article having a cured material layer, an antiviral article, wherein the cured product layer contains a cured product of a curable resin composition and antiviral particles, and the antiviral particles contain antiviral particles A consisting of particles containing a styrene resin.

2. 2. The antiviral article according to claim 1, comprising 0.5 to 20.0 parts by mass of the antiviral particles A relative to 100 parts by mass of the cured product.

3. The antiviral article according to claim 1 or 2, comprising the cured product layer on a substrate.

4. The antiviral article according to any one of claims 1 to 3, wherein the cured material layer further contains polyoxyethylene alkyl ether.

5. The antiviral article according to any one of claims 1 to 4, wherein the cured material layer further contains at least one agent selected from the group consisting of an antibacterial agent and an antiallergenic agent.

6. The antiviral article according to any one of claims 1 to 5, wherein the antiviral particles further contain antiviral particles B different from the antiviral particles A.

7. The antiviral article according to any one of claims 1 to 6, wherein the antiviral particles have two different particle size peaks.

8. 1. An antiviral resin composition comprising: a curable resin composition; and antiviral particles, wherein the antiviral particles contain antiviral particles A comprising particles containing a styrene resin.

9. The antiviral resin composition according to claim 8, further comprising a polyoxyethylene alkyl ether.

10. The antiviral resin composition according to claim 8 or 9, further comprising at least one selected from the group consisting of an antibacterial agent and an antiallergen.

11. The antiviral resin composition according to any one of claims 8 to 10, wherein the antiviral particles further contain antiviral particles B different from the antiviral particles A.

12. The antiviral resin composition according to any one of claims 8 to 11, wherein the antiviral particles have two different particle size peaks.

Images